메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Park Heejun (College of Pharmacy Duksung Women’s University) Ha Eun-Sol (College of Pharmacy Pusan National University) 김민수 (부산대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제51권 제6호
발행연도
2021.11
수록면
635 - 668 (34page)
DOI
10.1007/s40005-021-00529-9

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background There is a growing interest in the use of dry powder inhalers (DPIs) for administering high-dose drugs with low potency to the lungs as carrier-free formulations to treat both local pulmonary and systemic diseases. The main purpose of particle engineering and formulation design in the development of high-dose DPIs without carrier is to reduce the cohesive property of the particles and overcome the large inter-particulate interaction while enhancing powder dispersion and lung delivery upon inhalation and maintaining stability without agglomeration during storage. In particular, the cohesive property of high-dose DPIs can induce several physiological and physicochemical problems that must be improved. Area covered This review describes various particle surface modification methods, including sophisticated particle engineering (such as micronization) and formulation techniques, which are utilized to overcome the problems associated with high-dose DPIs. Expert opinion Currently, changing the cohesive property of particles through various micronization processes and improving the surface properties of particles through co-processing with limited excipients have been mainly used as efficient methods for particle surface modification. Using these technological principles, novel approaches have been attempted to develop inhalable drug particles, such as high-dose antibiotics and high-value biopharmaceuticals. The research on high-dose DPIs has expanded widely, and consequently, the drugs that received recent regulatory approvals have been successful based on the research results. Thus, it is expected that the next generation of DPIs will be safer and have higher therapeutic efficacy beyond the limitations of traditional high-dose DPIs.

목차

등록된 정보가 없습니다.

참고문헌 (272)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0